相关实验视频

Updated: Jan 13, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

作为严重缺血性中风的补充治疗的Bifidobacterium化合物制剂:系统性审查和元分析

Shenghua Lu^1,2, Yunfeng Yu¹, Yi Liu³

¹Department of Cardiovascular Medicine, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.

Frontiers in microbiology

|October 29, 2025

概括

与肠道营养 (EN) 相结合的Bifidobacterium化合物制剂 (BCP) 在严重缺血性中风 (SIS) 患者中显著改善了营养状况,神经功能和免疫功能. 这种组合治疗也减少了不良事件,显示出作为SIS辅助治疗的希望.

科学领域:

胃肠病学和肝病学
神经学神经学
免疫学免疫学免疫学

背景情况:

严重缺血性中风 (SIS) 带来了重大挑战,与肠道营养 (EN) 相结合的Bifidobacterium化合物制剂 (BCP) 的作用仍然不清楚.
评估BCP与EN结合的疗效和安全性对于优化患者的治疗结果至关重要.

研究的目的:

评估BCP与EN结合在改善SIS患者营养状况,神经功能,肠道屏障功能和免疫功能方面的有效性.
确定这种联合治疗方法的安全性.

主要方法:

在8个数据库中进行了系统的文献搜索,截至2025年1月1日.
包含777名患者的9项随机对照试验被纳入了元分析.
数据提取和偏差风险评估是独立进行的,使用RevMan 5.4软件进行统计分析.

主要成果:

BCP + EN显著改善了关键的营养标记 (白蛋白,总蛋白,前白蛋白,血红蛋白,转激素) 和神经功能 (格拉斯哥昏迷表,NIH中风表).
组合疗法通过降低二胺氧化酶和D-乳酸盐水平来增强肠道屏障功能,并通过增加IgA和IgG来增强免疫功能.
安全性分析表明,BCP+EN组的总不良事件,包括肺部感染,反流和腹,显著减少.

结论:

与EN结合的BCP在严重缺血性中风患者中显示出显著的益处.
这种联合治疗改善了营养状况,神经恢复,肠道屏障完整性和免疫反应.
研究结果表明,BCP+EN是严重缺血性中风的安全有效辅助治疗策略.

关键词:

双菌化合物制剂是双菌的复合制剂.双杆菌四倍活性的活性制剂双杆菌的三重可活性制剂进行元分析分析.益生菌是一种益生菌.严重的缺血性中风严重的缺血性中风

更多相关视频

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Bilateral Common Carotid Artery Occlusion as an Adequate Preconditioning Stimulus to Induce Early Ischemic Tolerance to Focal Cerebral Ischemia

Bilateral Common Carotid Artery Occlusion as an Adequate Preconditioning Stimulus to Induce Early Ischemic Tolerance to Focal Cerebral Ischemia

Published on: May 9, 2013

相关概念视频

Ischemic Heart Disease: Overview

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...